22 December 2025 ORYZON expands global patent protection for iadademstat with grant decision in Japan covering combinations with PD-1/PD-L1 inhibitors
15 December 2025 ORYZON announces the voting results of December 2025 Extraordinary General Shareholders' Meeting
9 December 2025 ORYZON presents data for iadademstat combinations in AML at the American Society of Hematology (ASH) 67th Annual Meeting
7 November 2025 ORYZON reports financial results and corporate update for quarter ended September 30, 2025
3 November 2025 ORYZON announces First‑Patient‑In (FPI) in RESTORE Phase Ib trial of iadademstat in sickle cell disease